Division of Teva Pharmaceutical Industries Ltd.
Latest From Cephalon Australia
Oncology-focused biotech, Polynoma, which is part of Hong Kong-based CK Life Sciences, has appointed Dr John Chiplin CEO. Dr Chiplin has over 25 years of biopharmaceutical experience having most recently served as founding CEO of Arana Therapeutics.
With the confirmation of second tranche payment of £2.85 million from Arana Therapeutics for an asset it sold in 2006, the UK immunology company, Scancell Holdings is now in a position to push towards its endgame of acquisition by a larger firm in search of a Phase II cancer vaccine asset and cancer vaccine platform.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
The inflammatory cascade linked to autoimmune disorders like rheumatoid arthritis, psoriasis, systemic lupus erythematosus, Crohn's disease, multiple sclerosis, ankylosing spondylitis, and transplant rejection causes heat. It also sparks biotech dealmaking. Lots of it and at high premiums for even midstage licenses. Even as the biodollars grow, the expansion of therapeutics and maturing of the marketplace could lead to new complexities that predict both opportunity and risk for emerging companies.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Peptide Technology Ltd.
- Peptech Ltd.
- Arana Therapeutics Ltd.
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
Steffan Nock, PhD, Acting CEO, Pres. US Ops.
Niall Henderson, CFO & Co. Secretary
Rob Crombie, PhD, VP, Bus. Dev. - Technology
Cliff Holloway, PhD, VP, Bus. Dev. - Products
- Contact Info
Phone: (61) 2 8061 9900
37 Epping Rd.
Macquarie Park, 2113